MA43650A - Formulations/compositions comprenant un inhibiteur de btk - Google Patents

Formulations/compositions comprenant un inhibiteur de btk

Info

Publication number
MA43650A
MA43650A MA043650A MA43650A MA43650A MA 43650 A MA43650 A MA 43650A MA 043650 A MA043650 A MA 043650A MA 43650 A MA43650 A MA 43650A MA 43650 A MA43650 A MA 43650A
Authority
MA
Morocco
Prior art keywords
formulations
compositions including
btk inhibitor
btk
inhibitor
Prior art date
Application number
MA043650A
Other languages
English (en)
Inventor
Manish Kumar Gupta
Nair Binuraj Krishnan
Parikshit Rameshrao Kulkarni
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA43650A publication Critical patent/MA43650A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043650A 2016-01-19 2017-01-18 Formulations/compositions comprenant un inhibiteur de btk MA43650A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621001987 2016-01-19

Publications (1)

Publication Number Publication Date
MA43650A true MA43650A (fr) 2018-11-28

Family

ID=57851068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043650A MA43650A (fr) 2016-01-19 2017-01-18 Formulations/compositions comprenant un inhibiteur de btk

Country Status (15)

Country Link
US (3) US20190290650A1 (fr)
EP (1) EP3405178A1 (fr)
JP (2) JP7336195B2 (fr)
KR (1) KR20180102150A (fr)
CN (2) CN114681462A (fr)
AR (1) AR107392A1 (fr)
AU (1) AU2017208473B2 (fr)
BR (1) BR112018014540B1 (fr)
CA (1) CA3008576A1 (fr)
EA (1) EA201891664A1 (fr)
HK (2) HK1259441A1 (fr)
MA (1) MA43650A (fr)
MX (2) MX2018008772A (fr)
TW (1) TWI794153B (fr)
WO (1) WO2017125424A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI662963B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
ES2971597T3 (es) * 2015-03-03 2024-06-06 Pharmacyclics Llc Formulaciones farmacéuticas del inhibidor de la tirosina quinasa de Bruton
JP7336195B2 (ja) * 2016-01-19 2023-08-31 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を含む製剤／組成物
CA3089537A1 (fr) 2018-01-20 2019-07-25 Natco Pharma Limited Compositions pharmaceutiques comprenant de l'ibrutinib
EP3575300A1 (fr) 2018-05-31 2019-12-04 Apotex Inc. Nouvelles formes cristallines d'ibrutinib
MA52874A (fr) 2018-06-15 2021-04-21 Janssen Pharmaceutica Nv Formulations/compositions comprenant de l'ibrutinib
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (fr) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CA2220451A1 (fr) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methodes et compositions pour ameliorer la digestion et l'absorption dans l'intestin grele
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CA2537254A1 (fr) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Procedes d'identification, de diagnostic et de prediction pour la survie des lymphomes
EP2532235A1 (fr) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
KR102054468B1 (ko) * 2011-10-19 2019-12-11 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
TWI662963B (zh) * 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
US20150140085A1 (en) * 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
MX2015011733A (es) * 2013-03-14 2016-04-25 Pharmacyclics Llc Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4.
WO2015071432A1 (fr) * 2013-11-14 2015-05-21 Sandoz Ag Compositions pharmaceutiques à base d'ibrutinib
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
JP7336195B2 (ja) * 2016-01-19 2023-08-31 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を含む製剤／組成物

Also Published As

Publication number Publication date
AR107392A1 (es) 2018-04-25
KR20180102150A (ko) 2018-09-14
CN108472258B (zh) 2024-05-24
HK1259441A1 (zh) 2019-11-29
TW201737918A (zh) 2017-11-01
JP2022105006A (ja) 2022-07-12
US20230364090A1 (en) 2023-11-16
BR112018014540B1 (pt) 2024-02-27
CA3008576A1 (fr) 2017-07-27
EA201891664A1 (ru) 2019-02-28
US20190290650A1 (en) 2019-09-26
JP7336195B2 (ja) 2023-08-31
WO2017125424A1 (fr) 2017-07-27
US20210169888A1 (en) 2021-06-10
AU2017208473B2 (en) 2022-04-21
BR112018014540A2 (pt) 2018-12-11
HK1259433A1 (zh) 2019-11-29
MX2018008772A (es) 2018-11-09
CN114681462A (zh) 2022-07-01
MX2022006817A (es) 2022-07-11
CN108472258A (zh) 2018-08-31
EP3405178A1 (fr) 2018-11-28
TWI794153B (zh) 2023-03-01
JP2019506450A (ja) 2019-03-07
AU2017208473A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
DK3688162T3 (da) Formuleringer
DK3359172T3 (da) Sammensætninger omfattende bakteriestammer
MA43649A (fr) Formulations/compositions comprenant un inhibiteur de btk
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3307288T3 (da) Sammensætninger omfattende bakteriestammer
DK3204025T3 (da) Sammensætninger omfattende bakteriestammer
DK3360559T3 (da) Sammensætninger omfattende bakteriestammer
DK3204024T3 (da) Sammensætninger omfattende bakteriestammer
MA43650A (fr) Formulations/compositions comprenant un inhibiteur de btk
DK3890488T3 (da) Herbicide sammensætninger
BR112017001922A2 (pt) composições fungicidas
DK3334726T3 (da) Plinabulinsammensætninger
MA43402A (fr) Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
DK3250182T3 (da) Dispergible sammensætninger
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3253377T3 (da) Monomethylfumarat-prodrug-sammensætninger
IT201700053475A1 (it) Calzatura componibile
DK3316857T3 (da) Multifasiske sammensætninger
DK3609464T3 (da) Xanthohumolbaserede sammensætninger
DK3528791T3 (da) Dispergible sammensætninger
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
DK3481206T3 (da) Forbedret bagerisammensætning
FR3027304B1 (fr) Compositions a base de 1,1,1,3,3-pentachloropropane
CL2016003154A1 (es) Composiciones herbicidas sólidas que contienen un fitoprotector
IT201700095717A1 (it) Composizione erbicida